Objective We analyzed the efficacy and safety of Preminent [losartan(50 mg/day)/HCTZ(12.5 mg/day)] compared to CodioMD [valsartan(80 mg/day)/HCTZ(6.25 mg/day)]. Methods In this study, 31 hypertensive patients after receiving 3 months of Preminent (Stage A) were enrolled. We applied a changeover with switching from Preminent to CodioMD (Stage B). We then applied another changeover with switching from CodioMD to Preminent after 3 months (Stage C).
Introduction
Better blood pressure (BP) control is associated with remarkable clinical benefits with regard to cardiovascular and renal protection. However, most hypertensive patients require two or more drugs to achieve the target of BP control (1) . Large-scale clinical trials, which evaluated the effects of angiotensin II type 1 receptor blockers (ARBs) on cardiovascular outcomes compared to other antihypertensive drugs, have also shown that thiazide diuretics are frequently added to ARBs to achieve adequate BP control (2) . Thus, combinations of ARBs and thiazide diuretics are recommended in various guidelines (3, 4) .
Seven kinds of single-pill fixed-dose combinations of ARB/hydrochlorothiazide (HCTZ) are available for clinical use in Japan (Supplementary Table) . They are able to divide into 4 groups (Group A, low-dose ARB/very low-dose first single-pill fixed-dose combination of ARB/HTCZ used in Japan. Second, 12.5 mg/day of HCTZ may be sufficient to induce a maximum effect when combined with an ARB, because HCTZ has been shown to have significant depressor effects in a dose-dependent manner at up to 12.5 mg/day, and there is no difference in the BP-lowering effect between 12.5 mg/day and 25 mg/day (5) . Third, losartan alone tends to decrease serum uric acid (UA) levels in patients with hypertension (HT) (6) , although HCTZ alone tends to increase these levels (3). Several reports have indicated that serum UA is an independent predictor of mortality in patients with coronary artery disease (CAD) (7, 8) . Previous studies have revealed that losartan/HCTZ has renal-protective (9) and anti-metabolic effects (6, 10) . When administered in combination with losartan and HCTZ, losartan may attenuate the increase in serum UA caused by HCTZ (6) . Since Preminent is the best-selling single-pill (Group B), we would like to determine whether it is possible to exchange Preminent with single-pill (Group C) with the same efficacy and safety for patients with hypertension. CodioMD [valsartan (80 mg/day)/HCTZ (6.25 mg/day)] in Group C was used because valsartan (80 mg/day) is the best-selling ARB in the world.
Materials and Methods

Study design
Thirty-three hypertensive patients who showed good BPcontrol after 3 months on Preminent (Stage A) were enrolled (Fig. 1 ). We applied a changeover with switching from Preminent to CodioMD (Stage B), and another changeover with switching from CodioMD to Preminent after 3 months (Stage C). We excluded patients with secondary HT, heart failure of NYHA grade III or IV, liver dysfunction, kidney dysfunction (defined as a serum creatinine level of more than 2.0 mg/dL), pregnancy, or a history of allergy to losartan, valsartan and/or HCTZ. The protocol in this study was approved by the ethics committee of Fukuoka University Hospital, and all subjects gave their informed consent to participate.
Evaluation of clinical parameters
We analyzed seated office systolic BP (SBP), diastolic BP (DBP) and pulse rate (PR), body weight (BW), serum and urinary levels of various parameters at the end of Stages A, B and C. BP was determined as the mean of two measurements obtained in an office setting by the conventional cuff method using a mercury sphygmomanometer after at least 5 minutes of rest. All of the blood and urinary samples were collected in the morning after the patients had fasted overnight. Data of serum levels of high sensitive-C reactive protein, high-density lipoprotein-cholesterol (HDL-C), lowdensity lipoprotein-cholesterol (LDL-C), triglycerides (TG), UA, creatinine (Cr), fasting glucose and hemoglobin A1c (HbA1c), sodium (Na) potassium (K), Cr and albumin (Alb) were collected for all patients.
Body mass index (BMI) was calculated as weight (kg)/ height (m) 2 . The characteristics of the patients, with regard to history of dyslipidemia (DL), diabetes mellitus (DM), hyperuricemia (HU), smoking status and medication use were obtained from medical records. Patients with LDL-C !140 mg/dL, TG !150 mg/dL, and/or HDL-C <40 mg/dL, or who were receiving lipid-lowering therapy, were considered to have DL. DM was defined using the American Diabetes Association criteria or the use of a glucose-lowering drug. HU was defined as a serum uric acid (UA) level of !7.0 mg/dL or the use of uric acid-lowering drugs.
Twenty-four hour ambulatory BP monitoring (ABPM)
At the end of each Stage (Stages A, B and C), ABPM was measured at 30-min intervals using ABPM devices (TM-2431, A&D, Tokyo, Japan). Average values of 24-h BP, morning BP (06:00-09:00), daytime BP (06:00-22:00) and nighttime BP (22:00-05:00) were calculated.
Statistical analysis
Statistical analysis was performed using the Stat View statistical software package (Stat View 5; SAS Institute Inc., Cary, NC, USA) at Fukuoka University (Fukuoka, Japan). Data are shown as the mean ± standard deviation (SD). The significance of differences between mean values was evaluated by a paired t-test or one-way analysis of variance followed by Fisher's protected-least-significant-difference test, as appropriate. Relationships between variables were tested by Pearson and Spearman correlations. A value of p<0.05 was considered significant. Table 1 shows the clinical characteristics of the 31 patients, [17 (55%) men and 14 (45%) women]. Two patients were withdrawn from the study because of sudden death (etiology unknown, n=1) and not visiting the hospital (n=1). The prevalence of DL, DM and HU was 48%, 10% and 23%, respectively. The mean age was 68±10 years, BMI was 24±3 kg/m 2 , and seated office SBP, DBP and PR were 120±10 mmHg, 69±8 mmHg and 70±10 beats/min, respectively. In addition, the percent use of calcium channel blocker (CCB), β-blocker and statin were 74, 6 and 34%, respectively; none of the patients received α-blocker. We did not change these medications throughout the study period.
Results
Patient characteristics
Changes in BP and PR
There were no significant changes in seated office BP and PR at the end of Stages A (120±10/69±8 mmHg and 69±8 beats/min), B (122±9/69±8 mmHg and 69±8 beats/min) and C (119±9/67±8 mmHg and 68±8 beats/min). Next, we analyzed ABP at the end of each Stage (Fig. 2 and 3 ). Continuous variables are expressed as mean ± SD. AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase: γ-GTP, γ-glutamyl transpeptidase; ALP, alkaline phosphatase; T-Bil, total bilirubin Cr, creatinine; eGFR, estimated glomerular filtration rate; LDL-C, low-density lipoprotein-cholesterol; HDL-C, high-density lipoprotein-cholesterol; TG, triglyceride; FBS, fasting blood sugar; Na, sodium; K, potassium; U-Na/U-Cr, urinary Na to urinary Cr ratio; U-K/U-Cr, urinary K to urinary Cr ratio; hs-CRP, high sensitive-C-reactive protein; BNP, brain natriuretic peptide.
. . (Fig. 3) . Preminent was better at lowering BP than CodioMD in the morning (Fig. 3b) . Therefore, a very low-dose of HCTZ was not sufficient for reducing BP compared with a lowdose of HCTZ.
Changes in biochemical parameters
As shown in Table 2 , there were no significant changes in .
Figure 5. Association between changes in the urinary albumin and creatinine ratio (ΔU-Alb/U-Cr) and changes in 24-h systolic BP (Δ24-h SBP) (a), 24-h diastolic blood pressure (Δ24-h DBP) (b) or daytime DBP (Δdaytime DBP) (c). Association between changes in serum uric acid (Δ serum UA) and Δ24-h DBP (d). Δindicates the value at the end of Stage B minus the value at the end of Stage A.
24-h DBP (mmHg)
biochemical parameters such as serum levels of Cr, Na, LDL-C and HDL-C except for serum UA and K, HbA1c and U-Alb/U-Cr (Fig. 4) . CodioMD significantly increased serum UA and K and U-Alb/U-Cr (at the end of Stage B) in Fig. 4 . Since these adverse effects did not disappear after changing to Preminent at the end of Stage C, we performed an additional 3-month follow-up (extended stage).
The subjects eventually required 6 months (at the end of the extended stage) to return to the levels observed at the end of Stage A. The results regarding serum UA did not change after we excluded a patient who was receiving an uricostatic drug (data not shown). Preminent , which contains losartan, may have beneficial effects in this regard. The levels of HbA1c at the end of Stages B and C were significantly lower than those at the end of Stage A, whereas there was no significant difference between the end of Stage B and the extended stage.
Associations between changes in BP and serum UA or U-Alb/Cr Fig. 5 shows the associations between changes in BP and U-Alb/U-Cr or serum UA. Although there was no association between Δ24-h SBP and ΔU-Alb/U-Cr [Δ= the value at the end of Stage B minus the value at the end of Stage A] (r=0.199, p=0.283), ΔU-Alb/U-Cr was significantly associated with Δ24-h DBP and Δdaytime DBP (r=0.361, p=0.046 and r=0.481, p=0.006, respectively) (Fig. 5a-c) . On the other hand, there were no associations between Δserum UA and Δ 24-h DBP (r=-0.260, p=0.158) (Fig. 5d) or Δ24-h SBP (r=-0.116, p=0.535, figure not shown). In addition, there were no associations between Δserum K and Δ24-h SBP (r=0.179, p=0.337) or Δ24-h DBP (r=-0.018, p=0.664, figure not shown).
Discussion
In the present study, Preminent was better at lowering 24 h-BP than CodioMD . In particular, Preminent was better at lowering BP in the morning. The change from Preminent to CodioMD was less effective at the levels of serum UA and U-Alb/Cr. Preminent , which contains losartan, may have beneficial effects.
In the present study, Preminent with 12.5 mg/day of HCTZ was better at lowering BP than CodioMD with 6.25 mg/day of HCTZ. There are two possible explanations for why Preminent induced a greater reduction in BP than CodioMD . First, although these two single-pill fixed-dose combination drugs contain different kinds of ARBs, the depressor effects of the ARBs, losartan and valsartan, are similar (11) . Thus, the different BP-lowering effects may depend on the dose of HCTZ. In fact, HCTZ at 12.5 mg/day had significantly greater depressor effects than at 6.25 mg/day, and there was no difference in the BP-lowering effects of HTCZ at 12.5 mg/day and 25 mg/day (5). Second, combination therapy with ARB/HTCZ showed enhanced BPlowering due to synergistic and additive effects on BP reduction provided by the different compounds. In a previous study, HCTZ at 12.5 mg/day, but not at 6.25 mg/day, significantly increased plasma renin activity (PRA) (5) . In this case, since the PRA activation induced by 12.5 mg/day of HTCZ may be significantly blocked by losartan, Preminent had a greater depressor effect than CodioMD .
Most ARBs have class (or common) effects, although recent clinical studies have demonstrated that not all ARBs have the same effects and some benefits conferred by ARBs may not be class effects, but rather molecular (or differential) effects (12) . Losartan in Preminent has a molecular effect, which is its uricosuric action. Losartan has been reported to have uricosuric action via the inhibition of urate transporter 1 (URAT1) in hypertensive patients (13) . Losartan and the URAT1 inhibitor benzbromarone increased the clearance value of urate and the creatinine ratio in hypertensive patients harboring the wild URAT1 gene, regardless of the presence of hypouricemia. On the other hand, although antihypertensive therapy with add-on low-dose ARB (olmesartan or valsartan) after stent implantation in patients with coronary artery disease was safe and achieved the target BP, valsartan significantly increased serum UA levels (14) . In this study, CodioMD , which contains valsartan, significantly increased serum UA compared with Preminent , which contains losartan. Thus, the results of this study were consistent with previous reports (12) (13) (14) .
ARBs dilate efferent arterioles directly in addition to their BP-lowering effects and reduce intraglomerular pressure. Consequently, ARBs decrease urinary protein excretion and prevent the progression of renal dysfunction. There are several possible explanations for why Preminent significantly decreased U-Alb/Cr compared with CodioMD in this study. First, Preminent significantly reduced BP compared with CodioMD . Second, losartan has been shown to have a significant shift to renal tissue compared to valsartan (15) .
Another important observation was the pattern of the BPlowering effect of Preminent . Preminent significantly reduced BP compared with CodioMD for 24-h BP, daytime BP, nighttime BP and morning BP based on ABPM data, but not seated office BP. The frequencies of onset of myocardial infarction, sudden cardiac death, and stroke show marked circadian variations, with parallel increases in the period from 6:00 am to noon (16) . As for nighttime BP, non-dippers have been shown to have cardiovascular risk greater than dippers (17) . Since Preminent significantly reduced BP compared with CodioMD in morning BP and nighttime BP, Preminent may be more useful for preventing cardio-and cerebrovascular diseases than CodioMD . In addition, although daytime U-Na and U-K excretion were not analyzed in this study, Bankir et al reported that daytime U-Na and U-K excretion are independently associated with nighttime SBP and SBP dipping (18) . Daytime urinary sodium excretion under 12.5 mg/day of HTCZ might be more useful for nighttime SBP and SBP dipping. In fact, Preminent also significantly reduced nighttime BP compared with CodioMD .
Study limitations
This study has two important limitations. First, the sample size is relatively small, which limits our ability to determine significance. Second, we applied a changeover with switching from Preminent to CodioMD , and thereafter a changeover with switching from CodioMD to Preminent . However, a crossover study would be preferable.
In conclusion, a single-pill, fixed-dose combination using Preminent showed significant 24-h BP-lowering effects and was safe compared with CodioMD .
The authors state that they have no Conflict of Interest (COI).
